FAKTOR-OPTIONSSCHEIN - GILEAD SCIENCES | Delayed Deutsche Boerse AG 06:26:04 2024-05-23 EDT | ||
| 0.37 EUR | -2.63% |
|
| 1 month | -7.32% | ||
| 3 months | +35.71% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-05-23 | 0.37 | -2.63% |
| 24-05-22 | 0.38 | 0.00% |
| 24-05-21 | 0.38 | +5.56% |
| 24-05-20 | 0.36 | -2.70% |
| 24-05-17 | 0.37 | 0.00% |
Delayed Quote Deutsche Boerse AG
Last update May 23, 2024 at 06:26 am
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
Société Générale
|
| WKN | SF3QYQ |
| ISIN | DE000SF3QYQ8 |
| Date issued | 2021-08-20 |
| Strike | 72.9 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.16 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 23.6 € |
|---|---|
| Lowest since issue | 0.11 € |
| Spread | 0.01 € |
| Spread % | 2.63% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
67.8
USD
Average target price
82.93
USD
Spread / Average Target
+22.31%
- Stock Market
- Certificates
- Certificat
